SCHEMBL6015013

SCHEMBL6015013

CC(C)(C)OC(CO)CO

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.37
MAPK1 P28482 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27055120 0.86 PRKCA (0.33) PRKCATSHR
SCHEMBL18027533 0.86 PRKCA (0.33) PRKCA
SCHEMBL224066 0.86 PRKCA (0.33) PRKCATSHR
SCHEMBL14349630 0.86 PRKCA (0.33) PRKCATSHR
SCHEMBL13805618 0.84 PRKCA (0.32) PRKCA
SCHEMBL16248890 0.84 PRKCA (0.32) PRKCA
SCHEMBL538535 0.82 MAPK1 (0.46) PRKCAMAPK1
SCHEMBL15290721 0.80 PRKCA (0.33) PRKCA
SCHEMBL23879558 0.80 PRKCA (0.31) PRKCA
SCHEMBL27964836 0.78 ALDH1A1 (0.41) PRKCAMAPK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3390589-A2 GTBE COMPOSITIONS, METHODS AND INSTALLATIONS FOR ENHANCED OCTANE BOOSTING Procede Holding B.V. (NL) 2018-10-24 EP claimed
WO-2017105246-A2 GTBE COMPOSITIONS, METHODS AND INSTALLATIONS FOR ENHANCED OCTANE BOOSTING PROCEDE HOLDING B.V. (NL) 2017-06-22 WO claimed
EP-1639072-A1 SOLVENT TREATMENT OF FABRIC ARTICLES The Procter & Gamble Company (US) 2006-03-29 EP claimed
US-20050223500-A1 Solvent treatment of fabric articles THE PROCTER & GAMBLE COMPANY 2005-10-13 US claimed
WO-2005003278-A1 SOLVENT TREATMENT OF FABRIC ARTICLES THE PROCTER & GAMBLE COMPANY (US) 2005-01-13 WO claimed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
EP-3390589-B1 GTBE COMPOSITIONS, METHODS AND INSTALLATIONS FOR ENHANCED OCTANE BOOSTING PROCEDE HOLDING B V (NL) 2022-02-23 EP disclosed
US-20200080014-A1 GTBE COMPOSITIONS, METHODS AND INSTALLATIONS FOR ENHANCED OCTANE BOOSTING PROCEDE HOLDING B.V. (NL) 2020-03-12 US disclosed
EP-3390589-A2 GTBE COMPOSITIONS, METHODS AND INSTALLATIONS FOR ENHANCED OCTANE BOOSTING Procede Holding B.V. (NL) 2018-10-24 EP disclosed
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC (US) 2018-07-12 US disclosed
US-20180163158-A1 OLFACTIVE COMPOSITIONS COMPRISING CYCLOHEXYL-ALKYL CARBINOLS P2 SCIENCE, INC. 2018-06-14 US disclosed
US-20180016217-A1 METHODS FOR PREPARING GLYCEROL TERT-BUTYL ETHERS SABIC GLOBAL TECHNOLOGIES, B.V. (NL) 2018-01-18 US disclosed
WO-2016120830-A1 METHODS FOR PREPARING GLYCEROL TERT-BUTYL ETHERS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2016-08-04 WO disclosed
WO-2015198268-A1 PROCESSES AND SYSTEMS FOR PREPARING GLYCEROL TERT-BUTYL ETHERS FROM GLYCEROL AND ISOBUTYLENE SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2015-12-30 WO disclosed
WO-2015140714-A1 PROCESSES AND SYSTEMS FOR GENERATING GLYCEROL ETHERS THROUGH TRANSETHERIFICATION SAUDI BASIC INDUSTRIES CORPORATION (SA) 2015-09-24 WO disclosed
US-20130031829-A1 METHOD FOR CONTINUOUSLY PRODUCING TERTIARY BUTYL ETHERS OF GLYCEROL TECHNISCHE UNIVERSITAET DORTMUND (DE) 2013-02-07 US disclosed
WO-2009066925-A2 METHOD OF MANUFACTURING GLYCEROL ETHER GS CALTEX CORPORATION (KR) 2009-05-28 WO disclosed
US-20070108405-A1 Compositions and methods for delivery of biologically active agents FH FAULDING & CO., LTD. (AU) 2007-05-17 US disclosed
US-20070108405-A1 Compositions and methods for delivery of biologically active agents FH FAULDING & CO., LTD. (AU) 2007-05-17 US disclosed
WO-1991009929-A1 STABILIZERS FOR AQUEOUS CLEANING FLUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1991-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180163158-A1 OLFACTIVE COMPOSITIONS COMPRISING CYCLOHEXYL-ALKYL CARBINOLS ACMSD, TAS2R1, MINK1 PRKCA 2894/4885MAPK1 2947/4885ALDH1A1 1201/4885
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, KAT2A PRKCA 3238/4885MAPK1 2588/4885ALDH1A1 482/4885
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 PRKCA 3387/4885MAPK1 1773/4885ALDH1A1 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.